Join
Live feed
·
PRReleasevia Quantisnow
RenovoRx Inc. logo

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

ByQuantisnow·Wall Street's wire, on your screen.
RNXT· RenovoRx Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RNXT (RenovoRx Inc.) and more on Quantisnow.